Patents Assigned to The Massachusetts General Hospital
-
Publication number: 20190264227Abstract: This invention relates generally to populations of microvesicles containing or otherwise associated with viral particles, methods of producing these purified populations, and methods of using these purified populations in a variety of diagnostic, therapeutic and/or prophylactic indications.Type: ApplicationFiled: March 20, 2019Publication date: August 29, 2019Applicant: THE GENERAL HOSPITAL CORPORATION d/b/a Massachusetts General HospitalInventors: Johan Karl Olov Skog, Casey Maguire
-
Publication number: 20190211000Abstract: The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome.Type: ApplicationFiled: December 21, 2018Publication date: July 11, 2019Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei Tsai, Ling Pan, Stephen J. Haggarty, Debasis Patnaik
-
Publication number: 20190175646Abstract: Described herein are methods and compositions relating to the treatment of benign skin tumors and/or malformations (e.g., seborrheic keratosis) by administering a proteasomal inhibitor and/or cationic inhibitor in combination with Zn2+ or Cu2+.Type: ApplicationFiled: November 28, 2016Publication date: June 13, 2019Applicant: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITALInventors: Anna MANDINOVA, Victor Allen NEEL
-
Patent number: 10301294Abstract: Disclosed are compounds that can be used for treating tuberculosis.Type: GrantFiled: March 12, 2014Date of Patent: May 28, 2019Assignees: THE BROAD INSTITUTE INC., MASSACHUSETTS GENERAL HOSPITAL, BRIGHAM AND WOMEN'S HOSPITALInventors: Timothy A. Lewis, Sivaraman Dandapani, Deborah Hung, Benito Munoz, Partha Nag, Sarah Grant, Tomohiko Kawate
-
Patent number: 10295624Abstract: A method of determining a decoupling matrix of a decoupling system for an array of coils of a parallel transmission magnetic resonance imaging (MRI) system includes obtaining impedance matrix data for the array of coils without the decoupling system, determining, based on the impedance matrix data for the array of coils, an objective function representative of deviation from a decoupled operating condition for the array of coils in which the array of coils are decoupled via the decoupling system, and defining, with a processor, a decoupling matrix representative of a set of impedances of the decoupling system with an iterative procedure that optimizes elements of the decoupling matrix to minimize the objective function and reach the decoupled operating condition.Type: GrantFiled: June 14, 2013Date of Patent: May 21, 2019Assignees: Massachusetts Institute of Technology, Massachusetts General Hospital, Siemens Healthcare GmbHInventors: Elfar Adalsteinsson, Luca Daniel, Bastien Guerin, Zohaib Mahmood, Markus Vester, Lawrence Wald
-
Publication number: 20190144867Abstract: A method for inhibiting metastasis of cancer cells is provided. Inhibitors of heparan sulfate (HS) or hyaluronic acid (HA) are applied to a tumor or a surgical location after removal of the bulk of the tumor. The inhibitors enzymatically cleave surface HS or HA; genetically modify cancer cells to decrease HS or HA production or interfere with the signaling pathway between HS or HA and a MMP or syndecan.Type: ApplicationFiled: September 19, 2016Publication date: May 16, 2019Applicants: Research Foundation of the City University of New York, Memorial Sloan Kettering Cancer Center, The General Hospital Corporation D/B/A Massachusetts General HospitalInventors: John M. TARBELL, Lance L. MUNN, Henry QAZI, Zhongdong SHI
-
Publication number: 20190099435Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.Type: ApplicationFiled: August 16, 2018Publication date: April 4, 2019Applicants: Children's Hospital Medical Center, The General Hospital Corporation d/b/a Massachusetts General Hospital, Instituto Nacional de Ciencias Medicas Y NutricionInventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
-
Patent number: 10238440Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.Type: GrantFiled: January 2, 2014Date of Patent: March 26, 2019Assignees: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, THE GENERAL HOSPITAL CORPORATION DBA MASSACHUSETTS GENERAL HOSPITALInventors: Stanley E Asnis, Peter D Asnis
-
Patent number: 10228313Abstract: In accordance with an embodiment of the invention, there is provided a method for: a) high-throughput, multiplexed, affinity-based separation of proteins—especially low abundance proteins—from complex biological mixtures such as serum; and b) high-throughput, multiplexed, affinity-based separation of cells—especially rare cells—from complex biological mixtures such as blood or blood fractions. The separation of proteins or cells is achieved based on differential binding to affinity-capture beads of different sizes and then sorting the protein-bound or cell-bound beads using the concept of centrifugal-induced Dean migration in a spiral microfluidic device. This method enables continuous-flow, high throughput affinity-separation of milligram-scale protein samples or millions of cells in minutes after binding.Type: GrantFiled: October 23, 2015Date of Patent: March 12, 2019Assignees: Massachusetts Institute of Technology, The Massachusetts General HospitalInventors: Aniruddh Sarkar, Han Wei Hou, Jongyoon Han, Galit Alter
-
Publication number: 20190038679Abstract: Described herein are compositions and methods relating to engineered bacteria which have a modified Type 3 Secretion System (T3SS) which permits them to deliver proteins to the extracellular space (e.g., as opposed to the intracellular space of a target cell as done with a wild-type T3SS). In some embodiments, the engineered bacteria comprise a transgenic T3SS. In some embodiments, the delivered protein is non-native or transgenic with respect to the engineered bacteria.Type: ApplicationFiled: February 8, 2017Publication date: February 7, 2019Applicant: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITALInventors: Cammie LESSER, Analise REEVES
-
Publication number: 20190038656Abstract: Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g., P. aeruginosa infection).Type: ApplicationFiled: October 3, 2016Publication date: February 7, 2019Applicants: Memorial Slooan-Kettering Cancer Center, The General Hospital Corporation d/b/a Massachusetts General Hospital, East Carolina UniversityInventors: Derek Shieh Tan, Cheng Ji, Indrajeet Sharma, Debarshi Pratihar, James P. Coleman, Everett C. Pesci, Laurence G. Rahme
-
Patent number: 10197646Abstract: A magnetic resonance imaging (MRI) system includes a plurality of transmitters to generate a parallel transmission radio frequency (RF) pulse, an array of coils coupled to the plurality of transmitters to apply the parallel transmission RF pulse to a subject, and a decoupling system connected to the plurality of transmitters and the array of coils. The decoupling system includes a plurality of hybrid couplers, each hybrid coupler of the plurality of hybrid couplers being coupled to a respective pair of the plurality of transmitters and to a respective pair of the array of coils. The plurality of hybrid couplers are configured to diagonalize an impedance matrix of the plurality of coils.Type: GrantFiled: May 6, 2015Date of Patent: February 5, 2019Assignees: Siemens Aktiengesellschaft, Massachusetts Institute of Technology, Massachusetts General Hospital CorporationInventors: Elfar Adalsteinsson, Luca Daniel, Bastien Guerin, Boris Keil, Zohaib Mahmood, Markus Vester, Lawrence Wald
-
Publication number: 20180327750Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.Type: ApplicationFiled: April 3, 2018Publication date: November 15, 2018Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
-
Publication number: 20180303373Abstract: A system and method for imaging in connection with electrical currents includes nanoparticles introduced into a region in which the electrical currents are present. A low-field magnetic resonance imaging (MRI) scanner detects an effect of a magnetic field generated by interaction of the nanoparticles with the electrical currents in the region. The MRI scanner operates at a magnetic field intensity below a level at which the nanoparticles would be magnetically saturated.Type: ApplicationFiled: April 21, 2017Publication date: October 25, 2018Applicants: The Charles Stark Draper Laboratory, Inc., The Massachusetts General HospitalInventors: Daniel K. Freeman, Matthew Rosen
-
Publication number: 20180280551Abstract: Provided herein are methods for producing site specific PEG modifications to single domain antibodies (e.g., VHHs). Methods for producing site-specific ally conjugated bivalent single domain antibodies (e.g., VHHs) are also provided. Methods for labeling (e.g., with a fluorophore or radionuclide) site-specifically PEGylated single domain antibodies and site-specifically conjugated bivalent single domain antibodies are also provided.Type: ApplicationFiled: October 1, 2016Publication date: October 4, 2018Applicants: Whitehead Institute for Biomedical Research, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Mohammad Rashidian, Hidde L. Ploegh, Neil Vasdev, Huan Steven Liang
-
Publication number: 20180252705Abstract: Methods of treating kidney diseases or disorders and methods of identifying agents for treatment of kidney diseases or disorders are provided. The method includes administering to a subject in need thereof, an effective amount of an agent which inhibits myeloid progenitor cells in the subject from producing soluble urokinase receptor (suPAR). The method includes administering the agent to a patient, where the patient, has an increased number of Gr-1 low cells relative to a control.Type: ApplicationFiled: March 25, 2016Publication date: September 6, 2018Applicants: Rush University Medical Center, Massachusetts General HospitalInventors: Jochen Reiser, Eunsil Hahm, Sanja Sever
-
Publication number: 20180221379Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).Type: ApplicationFiled: December 19, 2017Publication date: August 9, 2018Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Alykhan Shamji, Thomas Sundberg, Nathanael Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
-
Publication number: 20180223282Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.Type: ApplicationFiled: October 19, 2017Publication date: August 9, 2018Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20180156778Abstract: Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with N-acetylglucosamine-6-sulfatase and/or filamin-A, wherein immunological reactivity of the subject to one or more of N-acetylglucosamine-6-sulfatase or filamin-A, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays and kits for use with the methods are also disclosed.Type: ApplicationFiled: May 12, 2016Publication date: June 7, 2018Applicant: THE GENERAL HOSPITAL CORPORATION d/b/a MASSACHUSETTS GENERAL HOSPITALInventors: Allen C. Steere, Elise E. Drouin
-
Publication number: 20180099977Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: October 17, 2017Publication date: April 12, 2018Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang